Percutaneous repair of moderate-to-severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE-HF2 trial and comparison to COAPT and MITRA-FR trials

Heart, Artery and Coronary Diseases

Characteristics, determinants, and prognostic impact of severe tricuspid regurgitation in patients with atrial functional mitral regurgitation: Insights from the REVEAL-AFMR registry

Eur J Heart Fail

Kaneko T, Murata A, Amano M, Sato Y, Ohno Y, Obokata M, Sato K, Okada T, Fujita W, Morita K, Machino-Ohtsuka T, Abe Y, Minamino T, Kagiyama N

doi: 10.1002/ejhf.3624

Heart, Artery and Coronary Diseases

How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry

Am Heart J

Baldi C, Maio MD, Esposito L, Bellino M, Silverio A, Adamo M, Rubbio AP, De Felice F, Giordano A, Grasso C, Denti P, Godino C, De Marco F, Castriota F, Monteforte I, Mongiardo A, Petronio AS, Crimi G, Villa E, Bartorelli AL, Citro R, Galasso G, Tarantini G, Tamburino C, Bedogni F, GIOTTO registry

doi: 10.1016/j.ahj.2025.01.013

Further Publications

Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Patients With Cardiogenic Shock: A Systematic Review and Meta-Analysis

J Am Heart Assoc

Dimitriadis K, Soulaidopoulos S, Pyrpyris N, Sagris Μ, Aznaouridis K, Beneki E, Theofilis P, Tsioufis P, Tatakis F, Fragkoulis C, Shuvy M, Chrysohoou C, Aggeli K, Tsioufis K

doi: 10.1161/JAHA.124.034932

Heart Failure

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Am Heart J

Khan MS, Sauer AJ, Green CL, McDermott J, Khan MS, Chaudhry SP, Haghighat AR, Bennett MK, Martyn T, Shah H, Govil A, Stanis T, Albert NM, DeVore AD

doi: 10.1016/j.ahj.2025.06.001

COMMENTED

Heart Failure

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

★ 1 Recommended and commented by Prof. emer. Dr Ulrich Keller, Faculty Member

★ 2 Recommended by Prof. Dr Isabella Sudano, Faculty Member

Lancet Diabetes Endocrinol

Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators

doi: 10.1016/S2213-8587(24)00304-8

Heart FailureTherapy and Intervention

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair

Clin Res Cardiol

Magni V, Adamo M, Pezzola E, Rubbio AP, Giannini C, Masiero G, Grasso C, Denti P, Giordano A, De Marco F, Bartorelli AL, Montorfano M, Godino C, Baldi C, De Felice F, Mongiardo A, Monteforte I, Villa E, Crimi G, Tusa M, Testa L, Serafini L, Cani D, Guarini G, Huqi A, Sesana M, De Carlo M, Maisano F, Tarantini G, Tamburino C, Bedogni F, Metra M

doi: 10.1007/s00392-024-02490-7

Heart Failure

Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial

JACC Heart Fail

Ostrominski JW, Vaduganathan M, Claggett BL, Desai AS, Jhund PS, Lam CSP, Senni M, Shah SJ, Voors AA, Zannad F, Pitt B, Borentian M, Rohwedder K, Lay-Flurrie J, Lavagnino MA, McMurray JJV, Solomon SD

doi: 10.1016/j.jchf.2025.03.007

Heart Failure

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Eur J Heart Fail

Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C

doi: 10.1002/ejhf.3565

Heart Failure

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial

Lancet Healthy Longev

Balata M, Radbruch L, Hesse M, Westenfeld R, Neukirchen M, Pfister R, Batzler YN, Öztürk C, Kavsur R, Tiyerili V, Weltermann B, Pölsler R, Standl T, Nickenig G, Becher MU, Heart Failure Network Rhineland

doi: 10.1016/j.lanhl.2024.08.006

Related content

Characteristics, determinants, and prognostic impact of severe tricuspid regurgitation in patients with atrial functional mitral regurgitation: Insights from the REVEAL-AFMR registry

How the COAPT trial affected the selection of patients with secondary mitral regurgitation undergoing transcatheter edge-to-edge repair: insights from the GIOTTO Registry

Transcatheter Edge-to-Edge Repair for Severe Mitral Regurgitation in Patients With Cardiogenic Shock: A Systematic Review and Meta-Analysis

Rationale, Design, and Baseline Characteristics of the Virtual Care to Improve Heart Failure Outcomes (VITAL-HF) Trial

Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial

Impact of heart failure severity on the mortality benefit of mitral transcatheter edge-to-edge valve repair

Finerenone and New York Heart Association Functional Class in Heart Failure: The FINEARTS-HF Trial

Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry

Early integration of palliative care versus standard cardiac care for patients with heart failure (EPCHF): a multicentre, parallel, two-arm, open-label, randomised controlled trial